Stem cell market intelligence is defined as data relevant to the stem cell industry, gathered for the purpose of making informed business decisions. Business activities that market intelligence may support include:
- New product development
- Sales strategy
- Market strategy
- New client acquisition
Reasons to Invest in Stem Cell Market Intelligence
There are a huge number of reasons to invest in stem cell market intelligence, including that it will:
- Position yourself to approach investors – Without a doubt, investors will ask you for data on market size, market share, and market leaders.
- Target high-value opportunities – You need trend data to know where to focus your company’s time and resources.
- Increase sales from stem cell products – The fastest way to increase product sales is better understand the needs of your clients (that’s why we survey your end-users).
- Decrease risks associated with new product development – You don’t want to develop products that the market does not want or cannot support.
However, the most important purpose of stem cell market intelligence is to make smarter decisions, faster.
Benefits of Stem Cell Market Intelligence
You deserve to make informed, profitable decisions, while freeing yourself up to focus on more urgent issues that need your attention.
For the past 12 years, BioInformant has been tracking the stem cell industry for you, as well as interviewing stem cell industry executives.
To track this rapidly evolving industry, we use continuously maintained dashboards, combined with systems that alert us when the stem cell industry exhibits unexpected variation.
BioInformant’s Stem Cell Market Intelligence
BioInformant’s most popular stem cell market intelligence reports are highlighted below. Put simply, these are the products that your peers have been utilizing to improve their business performance.
The regenerative medicine industry is rapidly expanding, driven by a high volume of clinical trials, accelerated pathways for product approvals, and the potential for regenerative medicine therapies to revolutionize healthcare.
To characterize this rapidly growing industry, this database features 650+ regenerative medicine companies that are developing products for therapeutic use in humans.
It was originally developed in-house for our own purposes, but we have had more and more clients requesting access to it.
This 265-page global strategic report reveals key metrics impacting the cord blood banking industry, including rates of clinical trials, scientific publications, grants, patents, product launches, new market entrants, and M&A activity. It analyzes strategic partnerships, deal-making within the industry, and investments flowing into the industry, and crucial cord blood industry trends.
In addition to analyzing opportunities for storage of cord blood and cord tissue products, it considers opportunities for storage of other perinatal stem cell types.
Access to these market insights are vital, because the cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.
A contract manufacturing organization (CMO) is a company that serves cell therapy companies on a contract basis. Common cell therapy CMO services include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
In this 21-page, 50+ respondent survey, cell therapy manufacturing executives reveal when and why they choose to partner with a cell therapy contact manufacturing organization (CMO).
Importantly, it reveals the selection criteria that cell therapy executives use to select a CMO partner, as well as their perspectives on manufacturing capacity, geography, pure-play versus hybrid CMOs, and much more.
As the world’s first and only market research firm to specialize in the stem cell industry, BioInformant has unrivaled access to stem cell industry executives.
Using our connections, this 374-page interview package features interviews with 54 stem cell executives worldwide, giving you an inside look into the future of the stem cell industry from the very people who are creating it.
It includes interviews with leading executives worldwide, including:
- Kaz Hirao, CEO of Cellular Dynamics International, a Fujifilm company – CDI is the world’s largest manufacturer of pluripotent stem cells and differentiated cell types.
- Dr. Robert Hariri, CEO of Celularity, Inc. – Celularity raised $250 million in February 2018 to tackle aging and immunity using placental stem cells and other regenerative approaches.
- Dr. Riam Chammaa, Medical Director at the Canadian Centres for Regenerative Therapy (CCRT) – Dr. Chmamma is a Regulatory Specialist who explains how to interpret FDA regulation of cell and gene therapies under the new HCT/P guidelines.
Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is increasing with double-digit growth. In addition, 22% of stem cell researchers report using iPSC-derived cells or tissues within a research project.
There are now two iPSC-derived cell therapeutics in clinical trials, RIKEN’s iPSC-derived retinal sheets for AMD and Cynata Therapeutics’ CYP-001 for GvHD. Additionally, Kyoto University is launching the world’s first clinical trial utilizing an iPSC-derived therapeutics for Parkinson’s disease.
With both research and clinical activity expanding, the market for iPSC-derived cells and tissues is poised to experience rapid growth.
BioInformant.com is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving industry leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
What other questions do you have about stem cell market intelligence? Ask them in the comments below.